drugset / Trial / NCT01122615

Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

NCT01122615

Phase 1 Completed 23 enrolled M.D. Anderson Cancer Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of sunitinib and temsirolimus that can be given to patients with metastatic kidney cancer.

Timeline

Start
2010-05
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule Oral
Subject Temsirolimus Small molecule Intravenous

Indications